Jio BlackRock Said to Hire Kohli as CIO of Mutual-Fund Unit
Kohli will start in the third quarter of this year, the people said, asking not to be named as the information is private. He was managing partner and chief investment officer for hedge fund strategies at financial-services provider InCred Capital in Mumbai and previously worked at Avendus and ProAlpha Capital, according to his LinkedIn profile.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
2 minutes ago
- Forbes
Singapore Developers Gear Up To Launch Prime Residential Projects Amid Brisk Demand
Developers from City Developments to UOL Group are preparing to launch new luxury residential projects in the coming months amid resilient demand in the city-state despite the property curbs introduced by the government to rein in prices. Sales picked up in July, with developers selling 940 residential units (excluding government-subsidized executive condominiums), up 63% from a year ago, data released by the Urban Redevelopment Authority on Friday showed. While higher taxes continue to deter foreign buyers, Leonard Tay, research head at property consultancy Knight Frank, said he expects demand from Singapore citizens and permanent residents to remain strong. 'New citizens and permanent residents that favor high-rise living will be scouting for opportunities, setting down roots in a stable Singapore against the backdrop of a destabilising global environment,' Tay said by email, noting that Singapore welcomed 23,472 new citizens and 34,491 new permanent residents in 2023. Singapore has also seen an influx of wealthy families in recent years, attracted to the city-state's political stability and business friendly environment. Last year, the number of single family offices in the city-state increased 43% to more than 2,000. After seeing strong demand for prime properties in the central business district, billionaire Kwek Leng Beng's City Developments said it will start marketing the Zyon Grand, a 706-unit twin 62-story residential skyscraper, under construction near the Orchard Road shopping precinct, in the fourth quarter. Part of the mixed-used complex is a 36-story tower with 350 long-stay serviced apartments, retail shops, restaurants and a childcare center on the ground floor. 'The stellar sales performance of several newly launched projects, especially those in prime locations, is expected to boost overall buying sentiment.' Zyon Grand is located near the 524-unit River Green being built by Wing Tai Holdings, which sold 88% of the project during the weekend launch earlier this month. Billionaire Robert Kuok's Allgreen Properties is also developing a condominium in the area, the 596-unit Promenade Peak, which recorded a 54% takeup rate. 'The stellar sales performance of several newly launched projects, especially those in prime locations, is expected to boost overall buying sentiment,' Christine Sun, chief researcher and strategist at property consultancy Realion Group, said by email. 'The increased marketing activity and buying confidence of affluent investors will create a positive ripple effect in the broader market, motivating hesitant buyers or those waiting in the sidelines to invest.' UOL Group—controlled by the family of the late banking and real estate tycoon Wee Cho Yaw—and partner CapitaLand Development plans to start marketing Skye at Holland, a 666-unit residential condominium across two 40-story towers in the upscale Holland Village enclave, this quarter. The company has sold 64% of its 301-unit UpperHouse development on Orchard Boulevard since the July launch. Billionaire Quek Leng Chan's Guocoland is preparing to launch three new projects in the coming months through mid-2026. The Springleaf Residence, a 941-unit development across five towers on Upper Thomson Road in northern Singapore, will be launched this quarter, followed by a project on Faber Walk in the western part of the city-state by the end of the year, according to Guocoland. Guocoland is also developing a 455-unit waterfront condominium on River Valley Road, near the Orchard Road shopping precinct. The project is slated to be launched in the first half of 2026. Projects along the Singapore River have been popular, with Frasers Property—which is controlled by Thai billionaire Charoen Sirivadhanabhakdi and his family—selling 41% of the 348-unit Robertson Opus in July.
Yahoo
29 minutes ago
- Yahoo
Is There Now An Opportunity In TransDigm Group Incorporated (NYSE:TDG)?
Today we're going to take a look at the well-established TransDigm Group Incorporated (NYSE:TDG). The company's stock received a lot of attention from a substantial price movement on the NYSE over the last few months, increasing to US$1,621 at one point, and dropping to the lows of US$1,373. Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price. A question to answer is whether TransDigm Group's current trading price of US$1,388 reflective of the actual value of the large-cap? Or is it currently undervalued, providing us with the opportunity to buy? Let's take a look at TransDigm Group's outlook and value based on the most recent financial data to see if there are any catalysts for a price change. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. Is TransDigm Group Still Cheap? According to our valuation model, TransDigm Group seems to be fairly priced at around 0.57% above our intrinsic value, which means if you buy TransDigm Group today, you'd be paying a relatively fair price for it. And if you believe the company's true value is $1380.06, then there isn't really any room for the share price grow beyond what it's currently trading. Although, there may be an opportunity to buy in the future. This is because TransDigm Group's beta (a measure of share price volatility) is high, meaning its price movements will be exaggerated relative to the rest of the market. If the market is bearish, the company's shares will likely fall by more than the rest of the market, providing a prime buying opportunity. See our latest analysis for TransDigm Group What kind of growth will TransDigm Group generate? Investors looking for growth in their portfolio may want to consider the prospects of a company before buying its shares. Buying a great company with a robust outlook at a cheap price is always a good investment, so let's also take a look at the company's future expectations. TransDigm Group's earnings over the next few years are expected to increase by 47%, indicating a highly optimistic future ahead. This should lead to more robust cash flows, feeding into a higher share value. What This Means For You Are you a shareholder? It seems like the market has already priced in TDG's positive outlook, with shares trading around its fair value. However, there are also other important factors which we haven't considered today, such as the track record of its management team. Have these factors changed since the last time you looked at the stock? Will you have enough conviction to buy should the price fluctuates below the true value? Are you a potential investor? If you've been keeping an eye on TDG, now may not be the most advantageous time to buy, given it is trading around its fair value. However, the optimistic prospect is encouraging for the company, which means it's worth diving deeper into other factors such as the strength of its balance sheet, in order to take advantage of the next price drop. Keep in mind, when it comes to analysing a stock it's worth noting the risks involved. Be aware that TransDigm Group is showing 3 warning signs in our investment analysis and 2 of those can't be ignored... If you are no longer interested in TransDigm Group, you can use our free platform to see our list of over 50 other stocks with a high growth potential. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
29 minutes ago
- Yahoo
The three-year loss for CVS Health (NYSE:CVS) shareholders likely driven by its shrinking earnings
CVS Health Corporation (NYSE:CVS) shareholders should be happy to see the share price up 11% in the last month. But that doesn't change the fact that the returns over the last three years have been less than pleasing. After all, the share price is down 34% in the last three years, significantly under-performing the market. Although the past week has been more reassuring for shareholders, they're still in the red over the last three years, so let's see if the underlying business has been responsible for the decline. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement. CVS Health saw its EPS decline at a compound rate of 17% per year, over the last three years. This fall in the EPS is worse than the 13% compound annual share price fall. So, despite the prior disappointment, shareholders must have some confidence the situation will improve, longer term. The graphic below depicts how EPS has changed over time (unveil the exact values by clicking on the image). It's good to see that there was some significant insider buying in the last three months. That's a positive. That said, we think earnings and revenue growth trends are even more important factors to consider. It might be well worthwhile taking a look at our free report on CVS Health's earnings, revenue and cash flow. What About Dividends? When looking at investment returns, it is important to consider the difference between total shareholder return (TSR) and share price return. The TSR is a return calculation that accounts for the value of cash dividends (assuming that any dividend received was reinvested) and the calculated value of any discounted capital raisings and spin-offs. It's fair to say that the TSR gives a more complete picture for stocks that pay a dividend. We note that for CVS Health the TSR over the last 3 years was -26%, which is better than the share price return mentioned above. This is largely a result of its dividend payments! A Different Perspective It's good to see that CVS Health has rewarded shareholders with a total shareholder return of 23% in the last twelve months. And that does include the dividend. Since the one-year TSR is better than the five-year TSR (the latter coming in at 5% per year), it would seem that the stock's performance has improved in recent times. In the best case scenario, this may hint at some real business momentum, implying that now could be a great time to delve deeper. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. To that end, you should learn about the 3 warning signs we've spotted with CVS Health (including 1 which is a bit unpleasant) . If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: most of them are flying under the radar). Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
